Welcome to our dedicated page for USANA HEALTH SCIENCES SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
Ding Xia reported acquisition or exercise transactions in this Form 4 filing.
USANA Health Sciences director Xia Ding received a grant of restricted stock units. The award covers 6,527 RSUs, each representing a contingent right to receive one share of USANA common stock if vesting conditions are met.
The RSUs vest in four equal 25% installments on July 23, 2026, October 22, 2026, January 21, 2027, and April 22, 2027. Following this grant, Ding holds 6,527 restricted stock units directly, reflecting a routine equity-based compensation award rather than an open-market stock purchase or sale.
USANA Health Sciences Inc chief legal officer Joshua Foukas reported an open-market sale of company stock. On May 7, 2026, he sold 3,791 shares of Common Stock at $19.82 per share. After this transaction, his directly owned Common Stock holdings reported in this filing were reduced to 0 shares.
JOSHUA FOUKAS filed a Form 144 reporting a proposed sale of 3,791 shares of Common Stock as restricted stock with an activity date of 02/27/2026. The filing also shows a prior sale of 4,461 shares on 02/20/2026 for $95,220.05.
USANA Health Sciences reported fiscal Q1 2026 net sales of $250.2 million, essentially flat year over year, while profitability declined. Net earnings were $7.5 million versus $9.4 million a year ago, and diluted EPS fell to $0.41 from $0.49. Adjusted diluted EPS was $0.61 compared with $0.73, and Adjusted EBITDA was $28.4 million versus $29.8 million.
The Core Nutritional segment generated $204 million in net sales, down 3% year over year but up 7% sequentially, with 404,000 active customers, a 12% annual decline yet 4% sequential growth. Hiya posted $32 million in net sales, down 13% year over year, while Rise Wellness net sales surged to $14 million, up 741% year over year.
USANA ended the quarter with $163 million in cash and $14 million of debt. Management reiterated full‑year 2026 guidance, including consolidated net sales of $925 million to $1.0 billion, net earnings of $20 million to $27 million, diluted EPS of $1.11 to $1.45, and Adjusted EBITDA of $101 million to $109 million.
USANA Health Sciences director Timothy E. Wood reported routine equity compensation activity involving restricted stock units. On April 23, 2026, 1,057 restricted stock units converted into 1,057 shares of common stock, reflecting a derivative exercise with no cash purchase.
On the same date, 264 common shares were disposed of at $19.24 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold in the open market. Following these transactions, Wood directly held 10,613 shares of USANA common stock.
USANA Health Sciences director Frederic J Winssinger exercised restricted stock units into common stock, acquiring 1,057 shares. Following this transaction, he directly holds 8,101 shares of USANA common stock. Each restricted stock unit represents a contingent right to receive one share, with vesting in 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director J. Scott Nixon reported exercising 1,057 restricted stock units into an equal number of USANA common shares on April 23, 2026. Following this transaction, he directly holds 9,813 shares of common stock. Each restricted stock unit represented a right to receive one USANA share, and the units vested in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Gilbert A. Fuller exercised 1,057 restricted stock units into common stock. On April 23, 2026, 1,057 RSUs converted into 1,057 shares of USANA common stock at a stated price of $0.00 per share. After the transaction, he directly holds 1,057 common shares and no remaining RSUs under this grant.
Each restricted stock unit represented a contingent right to receive one share of common stock, with the grant vesting in 25% increments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Peggie Pelosi reported routine equity compensation activity involving restricted stock units and common shares. On April 23, 2026, 1,057 restricted stock units were exercised into 1,057 shares of common stock at a conversion price of $0.00 per share. To cover tax obligations, 668 common shares were disposed of at $19.24 per share as a tax-withholding disposition, rather than an open-market sale. After these transactions, Pelosi directly held 5,364 shares of USANA common stock.
USANA Health Sciences director John Turman Fleming exercised 1,057 Restricted Stock Units into Common Stock on April 23, 2026. The RSUs converted into 1,057 shares of USANA common stock, increasing his directly held position to 6,680 shares after the transaction. Each RSU represented a contingent right to receive one share of common stock, with this grant vesting in 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.